Clinical Trial Update: Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for capecitabine and tipifarnib in taxane-resistant metastatic breast cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Xeloda (capecitabine)
• ZARNESTRA

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Breast Cancer, Stage IV Breast Cancer | Phase 2 | Status: COMPLETED